Is Banner Display?
Off
Page Content
#ffffff
Video
Anonymous user
On
Authenticated user
On
Premium
On
Paid / Sponsored
On
Thumbnail
Controveries - Session 1
Speciality
Currency
Sub Speciality
Sub Sub Speciality
Short Description

Speaker Name: Dr. Yehuda Handelsman, Medical Director and Principal Investigator, Metabolic Institute of America, United States.

Follow this session to:

  • Evaluate how early SGLT2i-based therapy may address therapeutic inertia in T2DM.
  • Assess how SGLT2i-based FDCs may improve glycemic control and adherence.
  • Compare SGLT2i combinations with SU-based regimens for HbA1c, weight, BP, and renal outcomes.
  • Review key trial evidence supporting SGLT2i benefits in CV outcomes, HF, and CKD.
  • Interpret guideline updates positioning SGLT2i earlier in T2DM management.

 

Release Date
Is Paid
0
Most watched content
Off